Aretaieio Hospital, National and Kapodistrian University of Athens
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Clinical research at Aretaieio Hospital, National and Kapodistrian University of Athens is exploring cardiovascular diseases, with a focus on atrial fibrillation that appears after stress such as surgery or acute illness. The work is aimed at improving stroke prevention and reducing broader vascular complications.
- Evaluating non-vitamin K oral anticoagulants for better protection against stroke and systemic embolism
- Assessing whether treatment can lower vascular death and other major thromboembolic events
- Studying the management of stress-related atrial fibrillation in real-world clinical settings
This area of research is designed to clarify how best to prevent serious cardiovascular outcomes in patients whose arrhythmia develops transiently during stressful medical events.
Neoplasms
The site is also conducting trials in neoplasms, especially endometrial cancer with HER2 expression. These studies are focused on improving adjuvant treatment and measuring whether newer therapy options can extend disease-free survival compared with standard care.
- Comparing T-DXd with standard-of-care chemotherapy in HER2-expressing endometrial cancer
- Testing whether a targeted approach can improve disease-free survival after initial treatment
- Supporting better treatment selection for patients with endometrial malignancy linked to HER2
This research reflects a strong interest in refining cancer treatment strategies for patients with recurrent-risk gynecologic cancers and identifying more effective options than conventional therapy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Daiichi Sankyo Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Aretaieio Hospital, National and Kapodistrian University of Athens
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO) | Daiichi Sankyo Inc. | Phase III | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 1 | Unknown | 2024-01-29 | 2024-01-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.